Elicio Therapeutics Confirms Nasdaq Global Select Listing
Ticker: ELTX · Form: 8-K · Filed: Jan 16, 2024 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $21.0 million, $4.89 m |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance, administrative
TL;DR
**ELTX filed a routine 8-K confirming its Nasdaq listing; no new news.**
AI Summary
Elicio Therapeutics, Inc. filed an 8-K on January 16, 2024, to update its registration information, specifically noting its common stock is traded on The Nasdaq Global Select Market under the symbol ELTX. This filing is largely administrative, confirming the company's current trading status and its classification as an emerging growth company. For investors, this filing primarily serves as a routine confirmation of the company's listing and regulatory status, with no new material financial or operational developments disclosed.
Why It Matters
This filing confirms Elicio Therapeutics' listing on a major exchange, which is important for liquidity and visibility, but it doesn't announce any new business developments.
Risk Assessment
Risk Level: low — This 8-K is an administrative filing and does not introduce new financial or operational risks.
Analyst Insight
Investors should view this filing as a routine administrative update, confirming existing information. It does not provide new insights into the company's financial performance or future prospects, so no immediate action is warranted based solely on this 8-K.
Key Numbers
- $0.01 — par value per share (This is the nominal value assigned to each share of Elicio Therapeutics' common stock.)
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Global Select Market (company) — the exchange where Elicio Therapeutics' common stock is registered
- ELTX (company) — the trading symbol for Elicio Therapeutics' common stock
- January 16, 2024 (date) — date of earliest event reported and filing date
- $0.01 (dollar_amount) — par value per share of common stock
FAQ
What is the primary purpose of Elicio Therapeutics, Inc.'s 8-K filing on January 16, 2024?
The primary purpose of Elicio Therapeutics, Inc.'s 8-K filing on January 16, 2024, is to report 'Other Events' and confirm its registration details, specifically that its Common Stock, $0.01 par value per share, is registered pursuant to Section 12(b) of the Act and trades on The Nasdaq Global Select Market under the trading symbol ELTX.
What is the trading symbol and exchange for Elicio Therapeutics, Inc.'s common stock as stated in the filing?
As stated in the filing, the trading symbol for Elicio Therapeutics, Inc.'s common stock is ELTX, and it is registered on The Nasdaq Global Select Market.
Is Elicio Therapeutics, Inc. classified as an 'emerging growth company' according to this 8-K filing?
Yes, the filing indicates with a checkmark that Elicio Therapeutics, Inc. is an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
What is the par value per share of Elicio Therapeutics, Inc.'s common stock?
The par value per share of Elicio Therapeutics, Inc.'s common stock is $0.01, as specified in the filing.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was January 16, 2024.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-01-16 07:59:58
Key Financial Figures
- $0.01 — nge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq Glo
- $21.0 million — ng an aggregate offering price of up to $21.0 million from time to time through the Agents on
- $4.89 m — for net sale proceeds of approximately $4.89 million, after deducting sales commission
Filing Documents
- angn-20240116.htm (8-K) — 23KB
- 0001601485-24-000006.txt ( ) — 150KB
- angn-20240116.xsd (EX-101.SCH) — 2KB
- angn-20240116_lab.xml (EX-101.LAB) — 25KB
- angn-20240116_pre.xml (EX-101.PRE) — 13KB
- angn-20240116_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. At-the-Market Equity Offering Program Update On May 16, 2022, Elicio Therapeutics, Inc. (the "Company") entered into an At-The-Market Equity Offering Sales Agreement (the "Agreement") with Stifel, Nicolaus & Company, Incorporated ("Stifel") and Virtu Americas LLC ("Virtu" and together with Stifel, the "Agents") as sales agents and/or principal, pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $21.0 million from time to time through the Agents on terms set forth in the Agreement. Since the quarter ended September 30, 2023, the Company has issued and sold 584,170 shares of its common stock under the "at-the-market" equity offering program for net sale proceeds of approximately $4.89 million, after deducting sales commissions.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Date: January 16, 2024 Robert Connelly President and Chief Executive Officer (Principal Executive Officer)